ATE307572T1 - Verbesserte hmg coa reduktase-inhibitor formulierung mit verlängerter freisetzung - Google Patents
Verbesserte hmg coa reduktase-inhibitor formulierung mit verlängerter freisetzungInfo
- Publication number
- ATE307572T1 ATE307572T1 AT98960752T AT98960752T ATE307572T1 AT E307572 T1 ATE307572 T1 AT E307572T1 AT 98960752 T AT98960752 T AT 98960752T AT 98960752 T AT98960752 T AT 98960752T AT E307572 T1 ATE307572 T1 AT E307572T1
- Authority
- AT
- Austria
- Prior art keywords
- improved
- coa reductase
- release formulation
- extended release
- reductase inhibitor
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 238000013265 extended release Methods 0.000 title 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 239000011247 coating layer Substances 0.000 abstract 1
- 239000007891 compressed tablet Substances 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000002790 naphthalenes Chemical class 0.000 abstract 1
- 239000002357 osmotic agent Substances 0.000 abstract 1
- 230000003204 osmotic effect Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 229920003176 water-insoluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/989,253 US5916595A (en) | 1997-12-12 | 1997-12-12 | HMG co-reductase inhibitor |
| PCT/US1998/025766 WO1999030692A1 (en) | 1997-12-12 | 1998-12-04 | IMPROVED HMG CoA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE307572T1 true ATE307572T1 (de) | 2005-11-15 |
Family
ID=25534912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98960752T ATE307572T1 (de) | 1997-12-12 | 1998-12-04 | Verbesserte hmg coa reduktase-inhibitor formulierung mit verlängerter freisetzung |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5916595A (de) |
| EP (1) | EP1035842B1 (de) |
| JP (2) | JP4646400B2 (de) |
| AT (1) | ATE307572T1 (de) |
| AU (1) | AU737962B2 (de) |
| CA (1) | CA2315329C (de) |
| DE (1) | DE69832092T2 (de) |
| ES (1) | ES2252872T3 (de) |
| WO (1) | WO1999030692A1 (de) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060141036A1 (en) * | 1997-12-12 | 2006-06-29 | Andrx Labs Llc | HMG-CoA reductase inhibitor extended release formulation |
| US8524277B2 (en) * | 1998-03-06 | 2013-09-03 | Alza Corporation | Extended release dosage form |
| US6245357B1 (en) * | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
| SE9801429D0 (sv) * | 1998-04-23 | 1998-04-23 | Siemens Elema Ab | Förgasare |
| JP2002538202A (ja) * | 1999-03-08 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | HMG−CoAレダクターゼ阻害剤のジヒドロキシオープンアシッド及びその塩 |
| US6569461B1 (en) * | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
| EP1036563A1 (de) * | 1999-03-08 | 2000-09-20 | MERCK & CO. INC. | Dihydroxy offen Saüre und Salzen von hmg-coa reductase Inhibitoren |
| SE9903879D0 (sv) * | 1999-10-28 | 1999-10-28 | Ethical Pharmaceuticals Sweden | Multipor food protection |
| WO2001032162A1 (en) * | 1999-11-03 | 2001-05-10 | Howard J. Smith & Associates Pty Ltd | Liver selective therapy |
| US20020107173A1 (en) * | 1999-11-04 | 2002-08-08 | Lawrence Friedhoff | Method of treating amyloid beta precursor disorders |
| CA2389973A1 (en) * | 1999-11-04 | 2001-05-10 | Andrx Corporation | Method of treating amyloid beta precursor disorders |
| EP1233761B1 (de) * | 1999-11-22 | 2007-03-28 | ALZA Corporation | Osmotische darreichungsform mit zwei mantelschichten |
| US7108866B1 (en) | 1999-12-10 | 2006-09-19 | Biovall Laboratories International Srl | Chronotherapeutic diltiazem formulations and the administration thereof |
| US20060153914A1 (en) * | 1999-12-10 | 2006-07-13 | Biovail Laboratories International S.R.L. | Chronotherapeutic diltiazem formulations and the administration thereof |
| US6419956B1 (en) * | 1999-12-30 | 2002-07-16 | Ancile Pharmaceuticals | Odor-masking coating for a pharmaceutical preparation |
| MXPA02007254A (es) | 2000-02-04 | 2002-12-09 | Depomed Inc | Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero. |
| DE60211808T2 (de) * | 2001-07-31 | 2006-10-19 | Kabushiki Kaisha Kobe Seiko Sho (Kobe Steel, Ltd.), Kobe | Plattierte Kupferlegierung und Verfahren zu ihre Herstellung |
| US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
| US20030104052A1 (en) * | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| CA2409552A1 (en) * | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US6635675B2 (en) | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
| US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| MXPA04006780A (es) * | 2002-01-11 | 2005-06-08 | Athpharma Ltd | Formulaciones farmaceuticas de pravastatina y metodos para usarlas. |
| EP1905431A1 (de) * | 2002-01-11 | 2008-04-02 | Circ Pharma Research and Development Limited | Pharmazeutische Pravastatin-Formulierungen und Verfahren zu ihrer Verwendung |
| DE10209979A1 (de) * | 2002-03-07 | 2003-09-25 | Ratiopharm Gmbh | Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung |
| CA2379887C (en) * | 2002-04-09 | 2004-01-20 | Bernard Charles Sherman | Stable tablets comprising simvastatin |
| TW200404544A (en) * | 2002-06-17 | 2004-04-01 | Kowa Co | Controlled release pharmaceutical composition |
| US20040132806A1 (en) * | 2002-09-03 | 2004-07-08 | Jackie Butler | Pravastatin pharmaceutical formulations and methods of their use |
| US20040132802A1 (en) * | 2002-09-03 | 2004-07-08 | Jackie Butler | Pharmaceutical formulations and methods for modified release of statin drugs |
| SI21400A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska družba d.d. | Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze |
| BRPI0408442A (pt) * | 2003-03-17 | 2006-04-04 | Japan Tobacco Inc | método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato |
| KR20080008440A (ko) * | 2003-03-17 | 2008-01-23 | 니뽄 다바코 산교 가부시키가이샤 | Cetp 억제제의 약제학적 조성물 |
| TWI393560B (zh) * | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
| US8987322B2 (en) * | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| MY147202A (en) * | 2003-11-26 | 2012-11-14 | Novartis Ag | Compositions comprising organic compounds |
| KR100598326B1 (ko) * | 2004-04-10 | 2006-07-10 | 한미약품 주식회사 | HMG-CoA 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법 |
| AU2005247195A1 (en) * | 2004-05-27 | 2005-12-08 | Dexcel Pharma Technologies Ltd | Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins |
| US20050287185A1 (en) * | 2004-06-23 | 2005-12-29 | David Wong | Extended release oxybutynin formulation |
| US20060078615A1 (en) * | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
| WO2006054307A2 (en) * | 2004-11-22 | 2006-05-26 | Dexcel Pharma Technologies Ltd. | Controlled absorption of statins in the intestine |
| US20080260818A1 (en) * | 2005-03-28 | 2008-10-23 | Dexcel Pharma Technologies Ltd. | Controlled Absorption of Statins in the Intestine |
| AU2006263337A1 (en) * | 2005-06-29 | 2007-01-04 | Panacea Biotec Ltd. | Modified release pharmaceutical compositions on the basis of two polymers and processes thereof |
| US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| US20070098746A1 (en) * | 2005-11-02 | 2007-05-03 | Nichols William M | Multi-layered coating technology for taste masking |
| US8440695B2 (en) * | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
| US8124598B2 (en) * | 2006-09-14 | 2012-02-28 | Sharon Sageman | 7-keto DHEA for psychiatric use |
| US20100055173A1 (en) * | 2006-10-10 | 2010-03-04 | Adel Penhasi | Release of statins in the intestine |
| US20100160274A1 (en) * | 2007-09-07 | 2010-06-24 | Sharon Sageman | 7-KETO DHEA for Psychiatric Use |
| MX2011001384A (es) | 2008-08-06 | 2011-09-27 | Gosforth Ct Holdings Pty Ltd | Composiciones y metodos para tratar trastornos psiquiatricos. |
| MX2012007370A (es) * | 2009-12-22 | 2012-10-05 | Re Community Energy Llc | Cargas de alimentación de combustible diseñadas que contienen adsorbente. |
| CN102670557A (zh) * | 2011-03-14 | 2012-09-19 | 北京天衡药物研究院 | 洛伐他汀渗透泵型控释片 |
| GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
| AU2012345659B2 (en) | 2011-12-02 | 2017-09-28 | Synchroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| AR089765A1 (es) * | 2012-01-23 | 2014-09-17 | Bayer Oy | Un sistema para el suministro de un farmaco |
| CN104069502B (zh) | 2013-03-29 | 2018-02-16 | 北京罗诺强施医药技术研发中心有限公司 | 复合骨架材料及其药物组合物 |
| WO2014197744A1 (en) | 2013-06-05 | 2014-12-11 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| US20150133516A1 (en) | 2013-11-13 | 2015-05-14 | Brian K. Adams | Methods and Compositions for Treating ADHD |
| CN107920995A (zh) | 2015-07-02 | 2018-04-17 | 路易斯威尔大学研究基金会 | 用于递送miRNA的源自可食用植物的微囊泡组合物和用于治疗癌症的方法 |
| US11491114B2 (en) | 2016-10-12 | 2022-11-08 | Curioralrx, Llc | Formulations for enteric delivery of therapeutic agents |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5366738A (en) * | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
| GB8518301D0 (en) * | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
| US4976967A (en) * | 1987-08-03 | 1990-12-11 | Merck & Co., Inc. | Resin modulated drug delivery device for the delivery of HMG-CoA reductase inhibitor salts |
| US4814183A (en) * | 1987-08-31 | 1989-03-21 | Merck & Co., Inc. | Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins |
| US4915954A (en) * | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
| US4946686A (en) * | 1987-09-24 | 1990-08-07 | Merck & Co., Inc. | Solubility modulated drug delivery system |
| FR2655266B1 (fr) * | 1989-12-05 | 1992-04-03 | Smith Kline French Lab | Compositions pharmaceutiques a base de cimetidine. |
| US5300288A (en) * | 1991-04-05 | 1994-04-05 | Rohm And Haas Company | Composition and method for controlling cholesterol |
| US5543154A (en) * | 1991-12-27 | 1996-08-06 | Merck & Co., Inc. | Controlled release nifedipine delivery device |
| US5244916A (en) * | 1992-01-31 | 1993-09-14 | The Scripps Research Institute | Inhibition of respiratory burst using posttranslational modification inhibitors |
| US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
| US5350584A (en) * | 1992-06-26 | 1994-09-27 | Merck & Co., Inc. | Spheronization process using charged resins |
| US5260069A (en) * | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
| US5358502A (en) * | 1993-02-25 | 1994-10-25 | Pfizer Inc | PH-triggered osmotic bursting delivery devices |
| IN176897B (de) * | 1993-10-29 | 1996-09-28 | Cadila Lab Ltd | |
| US5582838A (en) * | 1994-12-22 | 1996-12-10 | Merck & Co., Inc. | Controlled release drug suspension delivery device |
| US5558879A (en) * | 1995-04-28 | 1996-09-24 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water soluble drugs in which a passageway is formed in situ |
| US5654005A (en) * | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
| JP3134187B2 (ja) * | 1996-03-07 | 2001-02-13 | 武田薬品工業株式会社 | 放出制御組成物 |
| US5837379A (en) * | 1997-01-31 | 1998-11-17 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
-
1997
- 1997-12-12 US US08/989,253 patent/US5916595A/en not_active Expired - Lifetime
-
1998
- 1998-12-04 CA CA002315329A patent/CA2315329C/en not_active Expired - Fee Related
- 1998-12-04 WO PCT/US1998/025766 patent/WO1999030692A1/en not_active Ceased
- 1998-12-04 AT AT98960752T patent/ATE307572T1/de active
- 1998-12-04 EP EP98960752A patent/EP1035842B1/de not_active Expired - Lifetime
- 1998-12-04 DE DE69832092T patent/DE69832092T2/de not_active Expired - Lifetime
- 1998-12-04 AU AU16275/99A patent/AU737962B2/en not_active Ceased
- 1998-12-04 JP JP2000538675A patent/JP4646400B2/ja not_active Expired - Fee Related
- 1998-12-04 ES ES98960752T patent/ES2252872T3/es not_active Expired - Lifetime
-
2010
- 2010-06-15 JP JP2010135848A patent/JP5132721B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1035842B1 (de) | 2005-10-26 |
| CA2315329C (en) | 2008-04-29 |
| US5916595A (en) | 1999-06-29 |
| CA2315329A1 (en) | 1999-06-24 |
| WO1999030692A1 (en) | 1999-06-24 |
| AU1627599A (en) | 1999-07-05 |
| DE69832092D1 (de) | 2005-12-01 |
| DE69832092T2 (de) | 2006-07-13 |
| AU737962B2 (en) | 2001-09-06 |
| JP2002508311A (ja) | 2002-03-19 |
| JP2010229150A (ja) | 2010-10-14 |
| JP4646400B2 (ja) | 2011-03-09 |
| ES2252872T3 (es) | 2006-05-16 |
| JP5132721B2 (ja) | 2013-01-30 |
| EP1035842A4 (de) | 2003-07-23 |
| EP1035842A1 (de) | 2000-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69832092D1 (de) | VERBESSERTE HMG CoA REDUKTASE-INHIBITOR FORMULIERUNG MIT VERLÄNGERTER FREISETZUNG | |
| FI973452A7 (fi) | Nauhoitettu annosmuoto aktiivisen aineen pidennettyyn jakamiseen | |
| ATE287260T1 (de) | Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung | |
| EP0815853A3 (de) | Langsam freisetzende Zubereitung für bioaktive Substanz mit einer sauren Gruppe | |
| WO2004108067A3 (en) | Programmed drug delivery system | |
| AU7562896A (en) | Water soluble films | |
| LU91122I2 (fr) | Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva). | |
| PT801560E (pt) | Um dispositivo de libertacao controlada de um farmaco em suspensao | |
| SV1998000104A (es) | Formas de dosificacion farmaceuticas solidas | |
| DE69925133D1 (de) | Pyrrolobenzodiazepine | |
| AU2016992A (en) | Multi-layered controlled release formulation | |
| ES2094694B1 (es) | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. | |
| AU4230900A (en) | Purposeful movement of human migratory cells away from an agent source | |
| WO2002024174A3 (en) | Sustained release composition containing clarithromycin | |
| ES2175362T3 (es) | Agente fitosanitario solido. | |
| BR0108753A (pt) | Corpos sólidos | |
| PT1263745E (pt) | 3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas substituidas e sua utilizacao para a inibicao da lipase sensivel a hormonas | |
| PT831826E (pt) | Composicao farmaceutica que inclui um inibidor de proteinase e um monoglicerideo | |
| NO995267D0 (no) | Leptin som en inhibitor av tumorcelleprofilering | |
| BR0013935A (pt) | IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos | |
| AU3483497A (en) | Solid solution of an antifungal agent with enhanced bioavailability | |
| ES2196620T3 (es) | Formulacion de liberacion prolongada que contiene venlafaxina. | |
| EP0761095A3 (de) | Vorbehandlungszusammensetzung für die Haut | |
| EP1291713A3 (de) | Thermisch entwickelbare Bildaufzeichnungsmaterialien, die eine Hydroxylgruppen enthaltende polymere Trennschicht aufweisen | |
| SE9601556D0 (sv) | New pharmaceutical formulation of a thrombin inhibitor for parenteral use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1035842 Country of ref document: EP |